- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05614739
Une étude de LOXO-435 chez des patients atteints de cancer avec un changement dans un gène appelé FGFR3 (FORAGER-1)
Une étude ouverte et multicentrique de LOXO-435 (LY3866288) dans les tumeurs malignes solides avancées avec altérations du FGFR3
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.
Aperçu de l'étude
Statut
Description détaillée
This is an open-label, multi-center, phase 1 study in participants with FGFR3-altered advanced solid tumor malignancy including metastatic urothelial cancer (UC), muscle-invasive bladder cancer (MIBC), and low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC). The study will be conducted in 2 phases. Phase 1a will assess safety, tolerability, and pharmacokinetics of Vepugratinib to determine the optimal dose for further expansion. Phase 1b will include dose expansion cohorts to evaluate the efficacy and safety of Vepugratinib as monotherapy or in combinations with other medicines that treat cancer.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- Numéro de téléphone: 1-317-615-4559
- E-mail: LillyTrials@Lilly.com
Sauvegarde des contacts de l'étude
- Nom: Physicians interested in becoming principal investigators please contact
- E-mail: clinical_inquiry_hub@lilly.com
Lieux d'étude
-
-
-
Bonn, Allemagne, 53127
- Pas encore de recrutement
- Universitaetsklinikum Bonn
-
München, Allemagne, 81675
- Recrutement
- Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
-
Tübingen, Allemagne, 72016
- Recrutement
- Universitaetsklinikum Tuebingen
-
-
-
-
-
Darlinghurst, Australie, NSW 2010
- Recrutement
- St Vincent's Hospital
-
Hunter Region, NSW, Australie, 2310
- Recrutement
- Calvary Mater Newcastle
-
St Leonards, Australie, 2065
- Recrutement
- GenesisCare North Shore
-
Sydney, Australie, 2109
- Recrutement
- Macquarie University
-
-
-
-
-
Toronto, Canada, M5G 2M9
- Recrutement
- Princess Margaret Hospital
-
Vancouver, Canada, V5Z 1J3
- Recrutement
- British Columbia Cancer Agency
-
-
-
-
-
Beijing, Chine, 100730
- Recrutement
- Beijing Hospital
-
Beijing, Chine, 100142
- Recrutement
- Beijing Cancer hospital
-
Guangdong, Chine, 510060
- Recrutement
- Sun Yat-Sen University- Cancer Center
-
Hangzhou, Chine, 310002
- Recrutement
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
-
Hangzhou, Chine, 310003
- Recrutement
- Zhejiang Provincial People's Hospital
-
Shanghai, Chine, 200000
- Recrutement
- Renji Hospital, Shanghai Jiaotong University School of Medicine
-
Tianjin, Chine, 300060
- Recrutement
- Tianjin Medical University Cancer Institute & Hospital
-
Xi'an, Chine, 710061
- Recrutement
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
-
-
-
Seoul, Corée du Sud, 05505
- Recrutement
- Asan Medical Center
-
Seoul, Corée du Sud, 03080
- Recrutement
- Seoul National University Hospital
-
Seoul, Corée du Sud, 03722
- Recrutement
- Severance Hospital, Yonsei University Health System
-
Seoul, Corée du Sud, 06351
- Recrutement
- Samsung Medical Center
-
-
-
-
-
Barcelona, Espagne, 08908
- Recrutement
- Institut Catala d'Oncologia - L'Hospitalet
-
Madrid, Espagne, 28041
- Recrutement
- Hospital Universitario 12 de Octubre
-
Madrid, Espagne, 28050
- Recrutement
- South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
-
Madrid, Espagne, 28033
- Recrutement
- Fundacion MD Anderson International Espana
-
Santander, Espagne, 39008
- Recrutement
- Hospital Universitario Marques De Valdecilla
-
-
-
-
-
Bordeaux, France, 33076
- Recrutement
- Institut Bergonie
-
Lyon, France, 69373
- Recrutement
- Centre Leon Berard
-
Villejuif, France, 94805
- Recrutement
- Institut Gustave Roussy
-
-
-
-
-
Petah Tikva, Israël, 49100
- Recrutement
- Rabin Medical Center, Beilinson Hospital
-
Tel HaShomer, Israël, 5265601
- Recrutement
- Sheba Medical Center
-
-
-
-
-
Milan, Italie, 20132
- Recrutement
- IRCCS Ospedale San Raffaele
-
Roma, Italie, 00168
- Recrutement
- UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
-
-
-
-
-
Chiba, Japon, 277-8577
- Recrutement
- National Cancer Center Hospital East
-
Nagoya, Japon, 464-8681
- Recrutement
- Aichi Cancer Center Hospital
-
Tokyo, Japon, 104-0045
- Recrutement
- National Cancer Center Hospital
-
Tokyo, Japon, 135-8550
- Recrutement
- Cancer Institute Hospital of JFCR
-
-
-
-
-
Bergen, Norvège, 5021
- Recrutement
- Haukeland University Hospital
-
Oslo, Norvège, 0450
- Recrutement
- Oslo University Hospital
-
-
-
-
-
GE Rotterdam, Pays-Bas, 3015
- Recrutement
- Erasmus MC
-
-
-
-
-
Manchester, Royaume-Uni, M20 4BX
- Recrutement
- The Christie NHS Foundation Trust
-
Sheffield, Royaume-Uni, S10 2SB
- Recrutement
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
Arizona
-
Tucson, Arizona, États-Unis, 85719
- Recrutement
- University of Arizona - Cancer Center
-
-
California
-
Duarte, California, États-Unis, 91010
- Recrutement
- City of Hope
-
Los Angeles, California, États-Unis, 90095
- Recrutement
- University of California, Los Angeles (UCLA) - Division of Hematology-Oncology
-
Orange, California, États-Unis, 92868
- Recrutement
- University of California - Irvine
-
Sacramento, California, États-Unis, 95817
- Recrutement
- University of California (UC) Davis Comprehensive Cancer Center
-
Stanford, California, États-Unis, 94305
- Recrutement
- Stanford Medicine Cancer Center
-
-
Florida
-
Orlando, Florida, États-Unis, 32804
- Recrutement
- Advent Health
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Emory University Hospital
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- The University of Chicago Medical Center (UCMC)
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Recrutement
- Indiana University (IU) Melvin and Bren Simon Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, États-Unis, 70809
- Recrutement
- Mary Bird Perkins Cancer Center
-
New Orleans, Louisiana, États-Unis, 70121
- Recrutement
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21231-2410
- Recrutement
- Johns Hopkins Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Recrutement
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201
- Recrutement
- Barbara Ann Karmanos Cancer Institute
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63108
- Recrutement
- Washington University in St. Louis
-
-
New York
-
New York, New York, États-Unis, 10021
- Recrutement
- Weill Cornell Medicine
-
New York, New York, États-Unis, 10029
- Recrutement
- Icahn School of Medicine at Mount Sinai
-
New York, New York, États-Unis, 10032
- Recrutement
- Columbia University
-
New York, New York, États-Unis, 10065
- Recrutement
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
-
New York, New York, États-Unis, 10016
- Recrutement
- New York University (NYU)
-
Rochester, New York, États-Unis, 14642
- Recrutement
- University of Rochester - Wilmot Cancer Institute
-
The Bronx, New York, États-Unis, 10467
- Recrutement
- Montefiore Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599
- Recrutement
- University of North Carolina (UNC) - Chapel Hill
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45267
- Recrutement
- University of Cincinnati Medical Center (UCMC)
-
Columbus, Ohio, États-Unis, 43210
- Recrutement
- The Ohio State University (OSU)
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73104
- Recrutement
- University of Oklahoma - Health Sciences Center
-
-
Pennsylvania
-
Lancaster, Pennsylvania, États-Unis, 17601
- Recrutement
- Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Recrutement
- University of Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Recrutement
- Thomas Jefferson University
-
Pittsburgh, Pennsylvania, États-Unis, 15213
- Recrutement
- University of Pittsburgh Medical Center
-
Pittsburgh, Pennsylvania, États-Unis, 15212
- Recrutement
- Allegheny General Hospital
-
-
South Carolina
-
Myrtle Beach, South Carolina, États-Unis, 29572
- Recrutement
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Tennessee Oncology
-
Nashville, Tennessee, États-Unis, 37212
- Recrutement
- Vanderbilt University Medical Center
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Sarah Cannon and HCA Research Institute
-
-
Texas
-
Dallas, Texas, États-Unis, 75244
- Recrutement
- University of Texas Southwestern
-
Dallas, Texas, États-Unis, 75251
- Recrutement
- Texas Oncology, P.A
-
Houston, Texas, États-Unis, 77030
- Recrutement
- MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84132
- Recrutement
- University of Utah
-
-
Vermont
-
Burlington, Vermont, États-Unis, 05401
- Recrutement
- University of Vermont Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Cohort A1, C1, D1, and D2: Locally advanced or metastatic solid tumor malignancy with a qualifying FGFR3 alteration.
-
Cohort A2, B2, B5 and B7: Urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration.
-
Cohorts B1 and B4: Urothelial cancer that is locally advanced or metastatic and have received prior erdafitinib.
-
Cohort B6: Muscle Invasive Bladder Cancer with a qualifying FGFR3 alteration.
-
Cohort B7: Urothelial cancer that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration and expression of human epidermal growth factor receptor 2 (HER2).
-
Cohort B8: Low Grade Intermediate Risk Non-Muscle Invasive Bladder cancer and a qualifying FGFR3 genetic alteration.
-
Measurability of disease:
- Cohort A1, D1, and D2: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1).
- Cohorts A2, B1, B2, B4, B5, B7, and C1: Measurable disease required as defined by RECIST v1.1.
- Cohort B8: Baseline disease which includes at least 1 lesion.
-
Have an Eastern Cooperative Oncology Group (ECOG) performance status of:
- 0 or 1 for Cohorts A1, A2, B5, B6, B7, and B8.
- Less than or equal to 2 for Cohorts B1, B2, B4, C1, DI and D2.
-
Cohort B6: Must be eligible for radical cystectomy plus pelvic lymph node dissection and agree to undergo curative intent standard radical cystectomy plus pelvic lymph node dissection.
Exclusion Criteria:
-
Participants with primary central nervous system (CNS) malignancy.
-
Untreated or uncontrolled CNS metastases.
-
Current evidence of corneal keratopathy or retinal disorder. Individuals with asymptomatic ophthalmic conditions may be eligible.
-
Any serious unresolved toxicities from prior therapy.
-
Significant cardiovascular disease.
-
Prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF).
-
Active uncontrolled systemic infection or other clinically significant medical conditions.
-
Participants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled.
-
Cohort D1 only:
- Have had renal transplantation.
- Have a known history of nephrotic syndrome.
- Have uncontrolled fluid overload, including clinically significant ascites, pleural effusion, or peripheral edema.
- Have uncontrolled hypertension.
- Are on hemodialysis or similar.
-
Cohort D2 only:
- Have a history of:
- Ventricular tachycardia or ventricular fibrillation.
- Hypertrophic obstructive cardiomyopathy unless managed concurrently with atrial fibrillation.
- Wolff-Parkinson-White syndrome.
- Second- or third-degree atrioventricular block unless a functioning pacemaker is in place.
- Heart rate less than (<) 50 bpm.
- Have any of these medical conditions:
- Severe respiratory insufficiency.
- Sleep apnea syndrome.
- Myasthenia gravis.
- Acute narrow-angle glaucoma.
- Active liver disease or clinically significant hepatic impairment.
- History of myopathy or rhabdomyolysis with any HMG-CoA reductase inhibitor.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Phase 1a: Cohort A1 Vepugratinib Monotherapy Dose Escalation
Vepugratinib administered orally |
Oral
Autres noms:
|
|
Expérimental: Phase 1a: Cohort A2 Vepugratinib Monotherapy Dose Optimization
Vepugratinib administered orally |
Oral
Autres noms:
|
|
Expérimental: Phase 1b: Cohort B1, B2, B4, C1, and D1 Vepugratinib Monotherapy Dose Expansion
Vepugratinib administered orally |
Oral
Autres noms:
|
|
Expérimental: Phase 1b: Cohort B5 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin
Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV |
IV Oral
Autres noms:
IV |
|
Expérimental: Phase 1b: MIBC Cohort B6 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin
Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV |
IV Oral
Autres noms:
IV |
|
Expérimental: Experimental: Phase 1b: Cohort B7 Vepugratinib Plus Trastuzumab Deruxtecan
Vepugratinib administered orally in combination with trastuzumab deruxtecan administered IV |
Oral
Autres noms:
IV |
|
Expérimental: Phase 1b: NMIBC Cohort B8 Vepugratinib Monotherapy Dose Expansion
Vepugratinib administered orally |
Oral
Autres noms:
|
|
Expérimental: Phase 1b: Cohort D2 (Drug to Drug Interaction)
Vepugratinib Plus Midazolam Plus Digoxin Plus Rosuvastatin (Lead-In Only) followed by Vepugratinib Monotherapy Vepugratinib administered orally Midazolam with digoxin with rosuvastatin administered orally once per cycle for 2 cycles. |
Oral
Autres noms:
Oral Oral Oral |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Overall Response Rate (ORR)
Délai: Up to Approximately 30 Months or 2.5 Years
|
Up to Approximately 30 Months or 2.5 Years
|
|
Pharmacokinetics (PK) of Vepugratinib: Area Under the Concentration versus Time Curve (AUC)
Délai: Up to 2 Months
|
Up to 2 Months
|
|
PK of Midazolam, Rosuvastatin, and Digoxin Administered Alone and in the Presence of Vepugratinib: Area Under the Concentration versus Time Curve (AUC[0-inf])
Délai: Up to 2 Months
|
Up to 2 Months
|
|
Complete Response Rate (CRR) in Participants with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC)
Délai: Up to approximately 24 months or 5 years
|
Up to approximately 24 months or 5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Change from Baseline in Bladder-Related Symptoms, Measured by Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) Subscale (BlCS)
Délai: Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 Day Cycles)
|
Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 Day Cycles)
|
|
Change from Baseline in Physical Function, Measured by FACT- Physical Well-Being Scale (PWB) Subscale
Délai: Up to Approximately 30 Months or 2.5 Years
|
Up to Approximately 30 Months or 2.5 Years
|
|
Event-Free Survival (EFS) in Participants with Muscle Invasive Bladder Cancer (MIBC)
Délai: Up to approximately 30 months or 2.5 years
|
Up to approximately 30 months or 2.5 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Processus pathologiques
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Processus néoplasiques
- Maladies urétérales
- Carcinome
- Maladies de la vessie urinaire
- Conditions pathologiques, signes et symptômes
- Tumeurs de la vessie non envahissantes sur le plan musculaire
- Tumeurs urétérales
- Métastase néoplasmique
- Tumeurs de la vessie urinaire
- Tumeurs urologiques
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Hydrocarbures
- Glucides
- Composés polycycliques
- Glycosides
- Amides
- Pyrimidines
- Stéroïdes
- Composés à anneau fusionné
- Hydrocarbures, halogénés
- Benzazépines
- Sulfonamides
- Sulfones
- Benzodiazépines
- Fluorobenzènes
- Hydrocarbures, fluorés
- Digitalis Glycosides
- Cardenolides
- Glycosides cardiaques
- Cardanolides
- Rosuvastatine calcique
- Midazolam
- Digoxine
- pembrolizumab
- enfortumab vedotin
- trastuzumab deruxecan
Autres numéros d'identification d'étude
- 18594
- LOXO-FG3-22001 (Autre identifiant: Eli Lilly and Company)
- J4G-OX-JZVA (Autre identifiant: Eli Lilly and Company)
- 2022-502755-59-00 (Autre identifiant: EU CTR #)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .